Liver & Intestine Transplant Perspective

 
 
  • Is It Covert or Overt Hepatic Encephalopathy? Hepatic encephalopathy manifests as a wide spectrum of abnormalities, ranging from subclinical alterations to coma. Careful testing, diagnosis, and treatment are required.
  • Portal Vein Thrombosis: Early Recognition, Improved Outcomes Although rare in the general populace, portal vein thrombosis can present secondary to various liver diseases and infections.
  • New Data Shine a Light on Liver Disease A roundup of the most impactful research on nonalcoholic fatty liver disease, chronic cholestatic liver diseases, and hepatotoxicity, as presented at this year's Digestive Disease Week.
  • Hepatitis C: Let's Get 'Real' Clinical trials have shown that current treatment approaches for hepatitis C are highly successful. Can this degree of success be attained in real-world populations?
  • A Simultaneous Liver-Kidney Transplant? Not So Fast   Do you really need that kidney first? Drs Berns and Reese discuss UNOS' new rules for kidney transplantation in liver transplant recipients.
  • New Data May Soon Reshape Transplantation Decisions in ESLD Dr William Balistreri provides an overview of the research that's adding compelling new ideas on how to enhance transplantation protocols for all types of patients.
  • Progress Noted in Treatment of Several Common Liver Diseases Dr William Balistreri provides an overview of the latest data on such disorders as alpha-1 antitrypsin deficiency, drug-induced liver injury, and parenteral nutrition-associated cholestasis.
  • Surveying the Latest Data in Fatty Liver Disease The recent Liver Meeting featured a wealth of studies on nonalcoholic fatty liver disease and steatohepatitis. Dr William Balistreri shines a light on those most likely to affect your practice.
  • A Focus on Hepatitis C: Outcomes Dr William Balistreri completes his three-part series on hepatitis C with a discussion about possible outcomes and a glimpse into the future of treatment.
  • A Focus on Hepatitis C: Novel Therapeutic Regimens In the second part of this three-part series, Dr William Balistreri continues his discussion of hepatitis C with a review of new antiviral agents and novel therapeutic strategies.
  • Liver Before Heart: Reversing Combined Organ Transplantation   Drs Sudhir Kushwaha and Rocky Daly share their considerations in reverse-order heart-liver transplant cases at Mayo's Heart Transplant Clinic.
  • A Focus on Hepatitis C: Cascade of Care In the first part of this three-part series on hepatitis C, Dr William Balistreri discusses the prevalence of this infection, screening methods, and access and barriers to care.
  • Treating CDI: Fresh or Frozen Feces?   Dr Lundberg describes a recent study of fecal microbiota transplantation for CDI and applauds the lack of FDA interference.
  • Sirolimus to Prevent Vasculopathy after Heart Transplant   Dr Sudhir Kushwaha describes vasculopathy following heart transplants and gives the lowdown on sirolimus-based immunosuppression.
  • Unsafe at Any Lunch? In the wake of several high-profile foodborne disease outbreaks, Dr William Balistreri details the clinical consequences, possible causes, and what can be done to stop them in the future.
  • Understanding Acute-on-Chronic Liver Failure A condition with a variety of classifications, associated complications, and manifestations, acute-on-chronic liver failure requires early identification to lessen the risk for patient mortality.
  • The Increasing Pace of Progress in Hepatology From obesity-related issues in children to the emerging role of the microbiome in multiple disorders, highlights from this year's Digestive Disease Week were as expansive as they were illuminating.
  • Screening for Hepatocellular Carcinoma Learn the risk factors for hepatocellular carcinoma, and who to screen, how often to screen, and what tools should be used.
  • Liver Diseases in Children: Challenges and Opportunities What progress has been made in the treatment of some of the most frequent liver diseases in children, and what does the future hold?
  • HCV Treatment: What Can I Do Now? What's Coming Next? As direct-acting antivirals continue to show success in HCV, the possibility for treatment expands to an even greater number of patient groups.